Copyright thehindubusinessline
Drugmaker Cipla clocked a 4 per cent growth in profit after tax at ₹1,351 crore for the second ended quarter ended September 30, 2025. “In Q2FY26, we delivered our highest-ever quarterly revenue of INR 7,589 crore, with a robust EBITDA margin of 25 per cent. What makes this performance commendable is the breadth and balance of our growth, driven by contributions across all our focused markets,” said Umang Vohra, Cipla’s outgoing MD and Global CEO. Pointing to the launch of Yurpeak (Tirzepatide), Cipla’s brand of Eli Lilly’s weightloss and diabetes drug Mounjaro announced just days ago, Vohra said “we mark a pivotal step into obesity care through our strategic partnership with Eli Lilly”. Commenting on the financial performance for the quarter, he said: “Our One-India business grew 7 per cent y-o-y (₹3,146 crore). Key therapies in branded prescription business continued to deliver strong market growth ....Trade generics recorded a double-digit growth and Anchor brands of consumer health business maintained leadership position. With a positive traction in our differentiated assets, the US business posted a revenue of $233 million during the quarter. In Q3 FY26, gRevlimid (generic) is expected to have a small contribution to the US revenue, with the base business expected to continue growing. Upcoming launches, subject to USFDA approvals, are expected to alleviate gRevlimid revenue decline over the next four quarters, though there may be a timing gap before the full benefit is realised.” Further, he said the One Africa business ($134 million) achieved a 5 per cent growth y-o-y; Emerging Markets and Europe ($110 million) delivered a revenue growth of 15 percent y-o-y on the back of deep market focus strategy. “Going ahead, the focus will be on growing our key markets, further building our flagship brands, investing in future pipeline as well as focusing on resolutions on the regulatory front,” he said. Published on October 30, 2025
